Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Kancha, Rama Krishna ^a   von Bubnoff, Nikolas ^a   Bartosch, Natalie ^a   Peschel, Christian ^a   Engh, Richard A ^b   Duyster, Justus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; LAPATINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; INCUBATION TIME; MOLECULAR CLONING; MUTATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; WILD TYPE; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENETICS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2;

EID: 80055032877     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026760     Document Type: Article

References (25)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science New York, NY 235: 177-182.
2. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, et al. (2004) Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
3. Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, et al. (2006) Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. International journal of cancer 119: 2586-2591.
4. Lee JW, Soung YH, Seo SH, Kim SY, Park CH, et al. (2006) Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. Clinical cancer research 12: 57-61.
5. Bekaii-Saab T, Williams N, Plass C, Calero MV, Eng C, (2006) A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma. BMC cancer 6: 278.
6. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, et al. (2005) Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clinical cancer research 11: 8105-8108.
7. Kubo T, Kuroda Y, Shimizu H, Kokubu A, Okada N, et al. (2009) Resequencing and Copy Number Analysis of the Human Tyrosine Kinase Gene Family in Poorly Differentiated Gastric Cancer. Carcinogenesis.
8. Sharma SV, Bell DW, Settleman J, Haber DA, (2007) Epidermal growth factor receptor mutations in lung cancer. Nature reviews 7: 169-181.
9. Kancha RK, Grundler R, Peschel C, Duyster J, (2007) Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Experimental hematology 35: 1522-1526.
10. Kancha RK, von Bubnoff N, Peschel C, Duyster J, (2009) Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clinical cancer research 15: 460-467.
11. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England journal of medicine 352: 786-792.
12. Trowe T, Boukouvala S, Calkins K, Cutler RE Jr, Fong R, et al. (2008) EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clinical cancer research 14: 2465-2475.
13. Gilmer TM, Cable L, Alligood K, Rusnak D, Spehar G, et al. (2008) Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib. Cancer research 68: 571-579.
14. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer cell 11: 217-227.
15. Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ, (2008) Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nature structural & molecular biology 15: 1109-1118.
16. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proceedings of the National Academy of Sciences of the United States of America 105: 2070-2075.
17. Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, et al. (2005) An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer research 65: 7096-7101.
18. Zhou W, Ercan D, Chen L, Yun CH, Li D, et al. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462: 1070-1074.
19. Kancha RK, Peschel C, Duyster J, The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors. Journal of thoracic oncology 6: 387-392.
20. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, et al. (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27: 4702-4711.
21. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, et al. (2007) PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer research 67: 11924-11932.
22. Minami Y, Shimamura T, Shah K, LaFramboise T, Glatt KA, et al. (2007) The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene 26: 5023-5027.
23. Stamos J, Sliwkowski MX, Eigenbrot C, (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. The Journal of biological chemistry 277: 46265-46272.
24. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer research 64: 6652-6659.
25. Qiu C, Tarrant MK, Choi SH, Sathyamurthy A, Bose R, et al. (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure London, England 16: 460-467.